

9 September 2019

**Deltex Medical Group plc**  
**("Deltex Medical" or "the Company")**

**Exercise of Options**

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM") announces that it has issued 1,250,000 new Ordinary Shares of 1 penny each in the capital of the Company ("Ordinary Shares") in connection with the exercise of options by a former employee granted under the Company's 2003 share option scheme. The options had an exercise price of 1 penny per share and the notice of exercise was received on 9 September 2019.

Application has been made for the 1,250,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on 13 September 2019. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of ordinary shares in issue following Admission will be 516,118,109. The Company does not hold any shares in treasury. Accordingly, the figure of 516,118,109 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

**For further information, please contact:-**

**Deltex Medical Group plc**  
Nigel Keen, Chairman  
Andy Mears, Chief Executive  
Jonathan Shaw, Group Finance Director

01243 774 837  
[investorinfo@deltexmedical.com](mailto:investorinfo@deltexmedical.com)

*Nominated Adviser & Broker*  
**Arden Partners plc**  
Ciaran Walsh  
Dan Gee-Summons

020 7614 5900

*Joint Broker*  
**Turner Pope Investments (TPI) Ltd**  
Andy Thacker

0203 621 4120  
[info@turnerpope.com](mailto:info@turnerpope.com)

**Notes for Editors**

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology, TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently save hospitals the costs of treating those complications.

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

**Group goal**

Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and through distribution arrangements in approximately 40 other countries.